Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?

Rituximab (RTX), a chimeric monoclonal anti-CD20 antibody has become part of the standard therapy for patients with CD20-expressing B-cell lymphoma and rheumatoid arthritis. After encouraging results with open studies in systemic lupus erythematosus (SLE), RTX has not shown its effectiveness in rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Lekpa, Fernando Kemta, Ngahane, Bertrand Hugo Mbatchou, Njonnou, Sylvain Raoul Simeni, Fouda, Hermine, Halle, Marie Patrice, Njankouo, Yacouba Mapoure, Dzudie, Anastase, Choukem, Simeon Pierre, Luma, Henry Namme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308936/
https://www.ncbi.nlm.nih.gov/pubmed/34367451
http://dx.doi.org/10.11604/pamj.2021.38.372.29087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308936/
https://www.ncbi.nlm.nih.gov/pubmed/34367451
http://dx.doi.org/10.11604/pamj.2021.38.372.29087

Ejemplares similares